Clinical Trial Update: Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the steady-state effect of the investigational compound BIA 6-512 on the pharmacokinetics of a single-dose Levodopa/Benserazide 200…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 6-512
• Levodopa/Benserazide 200/50 mg (Levodopa/Benserazide)
• Nebicapone 150 mg (Nebicapone)

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson Disease | Phase 1 | Status: COMPLETED